PRESS RELEASES

Date Title View
Toggle Summary Chimerix Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
DURHAM, N.C. , Jan. 25, 2021 (GLOBE NEWSWIRE) -- Chimerix , Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, announced today the closing of its previously announced underwritten public offering of
View HTML
Toggle Summary Chimerix Announces Pricing of Public Offering of Common Stock
DURHAM, N.C. , Jan. 20, 2021 (GLOBE NEWSWIRE) -- Chimerix , Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, announced today the pricing of its underwritten public offering of 11,765,000 shares of its
View HTML
Toggle Summary Chimerix Announces Proposed $75,000,000 Public Offering of Common Stock
DURHAM, N.C. , Jan. 19, 2021 (GLOBE NEWSWIRE) -- Chimerix , Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, announced today that it intends to offer and sell, subject to market and other conditions, up
View HTML
Toggle Summary Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program
ONC201 Registrational Trial for Recurrent H3 K27M-mutant Glioma Compelling Response Rates to Date; Defined Regulatory Path to Registration Pivotal Data Anticipated in 2021 to Support Potential Registration, Addressing an Estimated Market Opportunity of Greater than $500 Million Management to Host
View HTML
Toggle Summary Chimerix to Present at Virtual H.C. Wainwright BioConnect 2021 Conference
DURHAM, N.C. , Jan. 06, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman , Chief Executive Officer, will participate in a pre-recorded
View HTML
Toggle Summary Chimerix Announces FDA Acceptance of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox
FDA Grants Priority Review and Sets PDUFA Date for April 7, 2021 DURHAM, N.C. , Dec. 07, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that the U.S.
View HTML
Toggle Summary Chimerix to Present at Credit Suisse 29th Annual Healthcare Conference
DURHAM, N.C. , Nov. 05, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman , Chief Executive Officer, will present a corporate overview and
View HTML
Toggle Summary Chimerix Reports Third Quarter 2020 Financial Results and Provides Operational Update
– C ompleted R olling NDA S ubmissions for Both BCV Tablet and S uspension   Formulations as M edical C ountermeasure for S mallpox   – – F irst Patient Visit for DSTAT Phase 3 AML Study Expected in Early 2021 – – C ompany Well Capitalized Through Several Expected Upcoming Milestones – – C
View HTML
Toggle Summary Chimerix to Report Third Quarter 2020 Financial Results and Provide an Operational Update on November 5, 2020
DURHAM, N.C. , Oct. 29, 2020 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that it will host a live conference call and audio webcast on Thursday, November 5,
View HTML
Toggle Summary Chimerix to Participate in Upcoming Investor Conferences
DURHAM, N.C. , Sept. 10, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that management will participate in the following investor conferences in September:
View HTML